Baxter International, Inc. Faces Class Action Lawsuit Over Novum LVP Product

Strategic Insights -

Baxter International, Inc.'s recent product launch, the Novum LVP, has been plagued by systemic defects, including underinfusion, overinfusion, and complete non-delivery of fluids. This has exposed patients to risks of serious injury or death. As a result, a class action securities lawsuit has been filed against the company, alleging that defendants made false statements and/or concealed the truth about the product's safety and efficacy. The lawsuit seeks to recover losses of shareholders who were adversely affected by the alleged securities fraud between February 23, 2022, and July 30, 2025.

Key Takeaways:

  • The lawsuit alleges that Baxter International, Inc. made false statements about the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs.
  • The company was notified of multiple device malfunctions, injuries, and deaths from the defects, but failed to take adequate remedial measures.
  • The lawsuit seeks to recover losses of shareholders who suffered a loss on their Baxter International, Inc. investments between February 23, 2022, and July 30, 2025.
  • The lawsuit was filed by Levi & Korsinsky, LLP, a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders.
  • The firm has extensive expertise representing investors in complex securities litigation and has a team of over 70 employees.
  • Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven years in a row.

Statistics:

  • The lawsuit alleges that the company's attempts to address the defects through customer alerts were inadequate remedial measures.
  • The Novum LVP product launch occurred between February 23, 2022, and July 30, 2025.
  • The lawsuit was filed by Levi & Korsinsky, LLP, a firm with over 20 years of experience in securities litigation.

Sources:

  • Newsfile Corp.
  • Levi & Korsinsky, LLP
  • Baxter International, Inc. (NYSE: BAX)

Note: The dates mentioned in the press release are: October 29, 2025 (release date), February 23, 2022, and July 30, 2025. These dates are explicitly stated in the source material and are included in the analysis.